Adult Dosing

Prevention of relapse in vivax malaria

• 30 mg PO Daily x 14 days, after leaving malarious area
• Alt: 45 mg PO qwk x 8 weeks if borderline G6PD deficient
• Note: 15 mg base = 26.3 mg primaquine phosphate

Pediatric Dosing

Prevention of relapse in vivax malaria [Not FDA Approved]

• 0.6 mg [base]/kg PO daily x 14 days after leaving malarious area; Max: 30 mg PO daily x 14 days
• Note: 15 mg base = 26.3 mg primaquine phosphate

[Outline]

• Adult Dosing
• Pediatric Dosing

• Radical cure (prevention of relapse) of vivax malaria

• Hypersensitivity to any of the ingredients of the product
• Rheumatoid arthritis
• Lupus erythematosus
• Myelosuppression
• Concurrent use of hemolytic drugs or depressants
• History of quinacrine use
• Acutely ill patients with systemic disease such as SLE or RA

• Physicians should be familiar with the complete content of physician product information before prescribing primaquine

Renal Dose Adjustment

• Renal impairment: Dose adjustment not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustment not defined

• Hemolytic anemia may occur in patient with family or personal history of favism and G6PD deficiency. Discontinue the therapy if signs of hemolytic anemia like darkening of the urine, marked fall of hemoglobin or erythrocytic count occur
• Use of therapy during pregnancy should be avoided except when in the judgment of the physician the benefit outweighs the possible hazard
• Routine blood examinations particularly CBC and Hb determinations should be done during therapy

Cautions: Use cautiously in

• G6PD deficiency
• History of favism
• NADH methemoglobin reductase deficiency

Pregnancy Category:C

Breastfeeding: Safety unknown. However mother and infant should be tested for G6PD deficiency before primaquine is given to a woman who is breastfeeding. Very small amounts of antimalarial drugs are excreted in the breast milk of lactating women. Because the quantity of antimalarial drugs transferred in breast milk is insufficient to provide adequate protection against malaria, infants who require chemoprophylaxis must receive the recommended dosages of antimalarial drugs. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT Last accessed 14 March 2011).

• GI: Nausea, vomiting, epigastric distress, abdominal cramps
• HEMA: Leukopenia, hemolytic anemia, methemoglobinemia

• Antimalarial; exact mechanism of action unknown; but it bind and alter the properties of protozoal DNA
• Metabolized by liver; CYP450: Unknown
• Excreted in urine (minimally unchanged)
• Half-life: 3.7-7.4 hours

US Trade Name(s)

• Only generic available

US Availability

primaquine (generic)

• TABS: 15 mg

Canadian Trade Name(s)

• Only generic available

Canadian Availability

primaquine (generic)

• TABS: 15 mg

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• Primacin

Australian Availability

Primacin

• TABS: 7.5 mg

[Outline]

Antimicrobials

Antimalarials

Aminoquinolones

Infectious Disease

Antimalarials

Aminoquinolones

Pricing data from www.DrugStore.com in U.S.A.

• Primaquine Phosphate 26.3 MG TABS [Bottle] (SANOFI-AVENTIS U.S.)
  30 mg = $58.31
  90 mg = $146.93

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Drug Name: Primaquine phosphate 26.3 MG (primaquine 15 MG) Oral Tablet

Ingredient(s): Primaquine

Imprint: P97

Color(s): Pink

Shape: Round

Size (mm): 11.00

Score: 1

Inactive Ingredient(s): carnauba wax / hydroxypropyl methylcellulose / lactose / magnesium stearate / microcrystalline cellulose / polyethylene glycol 400 / polysorbate 80 / pregelatinized starch / red ferric oxide / talc / titanium dioxide

Drug Label Author:
Sanofi-Synthelabo Inc.

DEA Schedule:
Non-Scheduled